Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

PHASE3CompletedINTERVENTIONAL

Enrollment

599

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Human Immunodeficiency Virus Infections

Interventions

DRUG

lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)

LPV/r 800/200 mg once-daily (QD) tablet

DRUG

lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)

LPV/r 400/100 mg twice-daily (BID) tablet

Trial Locations (1)

Medical Information - Abbott (1-800-633-9110), Abbott Park